News|Articles|November 4, 2024
Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays (Executive Summary)
Author(s)Catalent
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
GSK and CAMP4 Partner to Advance RNA-Targeting Therapeutics
2
Novel Delivery Approaches of Biopharmaceuticals 2025
3
EMA Director Highlights Agency Achievements in 2025
4
FAQ: What Precision Analytics Have Done to Advance Next-Gen Biologics
5